UA77151C2 - Use of ramipril for prevention of cardiovascular events - Google Patents
Use of ramipril for prevention of cardiovascular events Download PDFInfo
- Publication number
- UA77151C2 UA77151C2 UA2002032518A UA2002032518A UA77151C2 UA 77151 C2 UA77151 C2 UA 77151C2 UA 2002032518 A UA2002032518 A UA 2002032518A UA 2002032518 A UA2002032518 A UA 2002032518A UA 77151 C2 UA77151 C2 UA 77151C2
- Authority
- UA
- Ukraine
- Prior art keywords
- patients
- ace
- ramipril
- inhibitor
- angiotensin
- Prior art date
Links
- 229960003401 ramipril Drugs 0.000 title abstract description 28
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 title abstract description 28
- 230000002265 prevention Effects 0.000 title abstract description 27
- 230000007211 cardiovascular event Effects 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract description 24
- 230000009467 reduction Effects 0.000 abstract description 15
- 150000003839 salts Chemical class 0.000 abstract description 7
- 208000009982 Ventricular Dysfunction Diseases 0.000 abstract description 2
- 230000006815 ventricular dysfunction Effects 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 description 40
- 208000010125 myocardial infarction Diseases 0.000 description 34
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 23
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 20
- 229960001138 acetylsalicylic acid Drugs 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 239000000902 placebo Substances 0.000 description 19
- 229940068196 placebo Drugs 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- 239000005541 ACE inhibitor Substances 0.000 description 17
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 230000002526 effect on cardiovascular system Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 239000002934 diuretic Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 13
- 102000015427 Angiotensins Human genes 0.000 description 12
- 108010064733 Angiotensins Proteins 0.000 description 12
- 208000010496 Heart Arrest Diseases 0.000 description 12
- 206010020772 Hypertension Diseases 0.000 description 12
- 239000002220 antihypertensive agent Substances 0.000 description 12
- 230000034994 death Effects 0.000 description 12
- 231100000517 death Toxicity 0.000 description 12
- 230000036454 renin-angiotensin system Effects 0.000 description 12
- 208000002249 Diabetes Complications Diseases 0.000 description 11
- 206010012655 Diabetic complications Diseases 0.000 description 11
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 230000001882 diuretic effect Effects 0.000 description 10
- -1 M5-41 Chemical compound 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000000250 revascularization Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 206010007559 Cardiac failure congestive Diseases 0.000 description 8
- 229940030600 antihypertensive agent Drugs 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 101800000733 Angiotensin-2 Proteins 0.000 description 7
- 102400000345 Angiotensin-2 Human genes 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 7
- 239000003529 anticholesteremic agent Substances 0.000 description 7
- 229940127226 anticholesterol agent Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010002383 Angina Pectoris Diseases 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 229950006323 angiotensin ii Drugs 0.000 description 6
- 229940126601 medicinal product Drugs 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 108010061435 Enalapril Proteins 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 229940030606 diuretics Drugs 0.000 description 5
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 4
- 101800000734 Angiotensin-1 Proteins 0.000 description 4
- 102400000344 Angiotensin-1 Human genes 0.000 description 4
- 108010007859 Lisinopril Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229940127088 antihypertensive drug Drugs 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 229940097320 beta blocking agent Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 229960000873 enalapril Drugs 0.000 description 4
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 229960003765 fluvastatin Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229960002394 lisinopril Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960002965 pravastatin Drugs 0.000 description 4
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 4
- 239000002461 renin inhibitor Substances 0.000 description 4
- 229940086526 renin-inhibitors Drugs 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010027525 Microalbuminuria Diseases 0.000 description 3
- 108090000783 Renin Proteins 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 238000002647 laser therapy Methods 0.000 description 3
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 229960001455 quinapril Drugs 0.000 description 3
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 3
- FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 description 3
- 229960001007 quinaprilat Drugs 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- 229960002909 spirapril Drugs 0.000 description 3
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 3
- 108700035424 spirapril Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960004084 temocapril Drugs 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NPAICBCRXGSAJJ-UHFFFAOYSA-N 3,6-dihydroxyphenazine-1-carboxylic acid Chemical compound C1=CC=C2N=C3C(C(=O)O)=CC(O)=CC3=NC2=C1O NPAICBCRXGSAJJ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 2
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229960005227 delapril Drugs 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 229960001195 imidapril Drugs 0.000 description 2
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- 229960005170 moexipril Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229960002582 perindopril Drugs 0.000 description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
- 208000030613 peripheral artery disease Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229960002231 ramiprilat Drugs 0.000 description 2
- KEDYTOTWMPBSLG-HILJTLORSA-N ramiprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 KEDYTOTWMPBSLG-HILJTLORSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229960002051 trandolapril Drugs 0.000 description 2
- 229960002651 trandolaprilat Drugs 0.000 description 2
- AHYHTSYNOHNUSH-HXFGRODQSA-N trandolaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)C(O)=O)CC1=CC=CC=C1 AHYHTSYNOHNUSH-HXFGRODQSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- DEEOVDONDDERBX-MUDWFXPSSA-N (2S)-6-amino-2-[[(1S,4R,10S,19S,22S,25S,28S,31S,34R,37S,43S,46S,47S,50R,53S,56S,62S)-50-amino-43-(2-amino-2-oxoethyl)-56-(3-amino-3-oxopropyl)-10-benzyl-37-(carboxymethyl)-31-(hydroxymethyl)-28-(1H-indol-3-ylmethyl)-47,62-dimethyl-7-methylidene-22-(2-methylpropyl)-2,5,8,11,14,20,23,26,29,32,35,38,41,44,51,54,57-heptadecaoxo-53-propan-2-yl-48,60,63-trithia-3,6,9,12,15,21,24,27,30,33,36,39,42,45,52,55,58-heptadecazatetracyclo[32.24.3.34,25.015,19]tetrahexacontane-46-carbonyl]amino]hexanoic acid Chemical compound CC(C)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)C(=C)NC(=O)[C@@H]2CS[C@@H](C)[C@@H](NC1=O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](CO)C(=O)N[C@H]1CSC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CS[C@@H](C)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC1=O)C(=O)N[C@@H](CCCCN)C(O)=O)C(C)C)C(=O)N2 DEEOVDONDDERBX-MUDWFXPSSA-N 0.000 description 1
- QIJLJZOGPPQCOG-NFAWXSAZSA-N (2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)C1CCCCC1 QIJLJZOGPPQCOG-NFAWXSAZSA-N 0.000 description 1
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 1
- OMGPCTGQLHHVDU-SSXGPBTGSA-N (2s)-3-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3-azabicyclo[2.2.2]octane-2-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C2CCC1CC2)C(O)=O)CC1=CC=CC=C1 OMGPCTGQLHHVDU-SSXGPBTGSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-RPQBTBOMSA-M (3S,5R)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-RPQBTBOMSA-M 0.000 description 1
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- KRGPXXHMOXVMMM-CIUDSAMLSA-N (S,S,S)-nicotianamine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC[NH2+][C@H](C([O-])=O)CC[NH+]1CC[C@H]1C([O-])=O KRGPXXHMOXVMMM-CIUDSAMLSA-N 0.000 description 1
- RWNNRGBCWXOVAC-UHFFFAOYSA-N 1,4-bis[bis(aziridin-1-yl)phosphoryl]piperazine Chemical compound C1CN1P(N1CCN(CC1)P(=O)(N1CC1)N1CC1)(=O)N1CC1 RWNNRGBCWXOVAC-UHFFFAOYSA-N 0.000 description 1
- IFYLTXNCFVRALQ-UHFFFAOYSA-N 1-[6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]pyrrolidine-2-carboxylic acid Chemical compound C1CCC(C(O)=O)N1C(=O)C(CCCCN)OP(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- UUPNFNCKGJOLQE-UHFFFAOYSA-N 2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)imidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C(O)=O)C=C1 UUPNFNCKGJOLQE-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 229940123471 Angiotensin II agonist Drugs 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000699762 Homo sapiens RNA 3'-terminal phosphate cyclase Proteins 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- XRKXJJYSKUIIEN-LLVKDONJSA-N Pivopril Chemical compound CC(C)(C)C(=O)SC[C@@H](C)C(=O)N(CC(O)=O)C1CCCC1 XRKXJJYSKUIIEN-LLVKDONJSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100029143 RNA 3'-terminal phosphate cyclase Human genes 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 239000005478 Saprisartan Substances 0.000 description 1
- DUEWVPTZCSAMNB-UHFFFAOYSA-N Saprisartan Chemical compound NC(=O)C=1N(CC=2C=C3C(Br)=C(OC3=CC=2)C=2C(=CC=CC=2)NS(=O)(=O)C(F)(F)F)C(CC)=NC=1C1CC1 DUEWVPTZCSAMNB-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 108010055869 ancovenin Proteins 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960004067 benazeprilat Drugs 0.000 description 1
- MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- KKBIUAUSZKGNOA-HNAYVOBHSA-N benzyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate Chemical compound O=C([C@@H](NC(=O)[C@@H](CSC(C)=O)CC=1C=C2OCOC2=CC=1)C)OCC1=CC=CC=C1 KKBIUAUSZKGNOA-HNAYVOBHSA-N 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229950006523 cilexetil Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000009937 cyclo 3 Substances 0.000 description 1
- VTDCYOLLYVAJSY-UHFFFAOYSA-N cyclohexyl propan-2-yl carbonate Chemical compound CC(C)OC(=O)OC1CCCCC1 VTDCYOLLYVAJSY-UHFFFAOYSA-N 0.000 description 1
- 229960003176 cyclothiazide Drugs 0.000 description 1
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
- 229950003040 dalvastatin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- CCYTUJPXAFHZHC-UHFFFAOYSA-L disodium;4-[[2-butyl-5-(carboxylatomethyl)-4-chloroimidazol-1-yl]methyl]benzoate Chemical compound [Na+].[Na+].CCCCC1=NC(Cl)=C(CC([O-])=O)N1CC1=CC=C(C([O-])=O)C=C1 CCYTUJPXAFHZHC-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- 229960002680 enalaprilat Drugs 0.000 description 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 229950009810 indolapril Drugs 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N indolyl-2-carboxylic acid Natural products C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- AXTCRUUITQKBAV-KBPBESRZSA-N libenzapril Chemical compound OC(=O)CN1C(=O)[C@@H](N[C@@H](CCCCN)C(O)=O)CCC2=CC=CC=C21 AXTCRUUITQKBAV-KBPBESRZSA-N 0.000 description 1
- 229950001218 libenzapril Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960003739 methyclothiazide Drugs 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950006549 moveltipril Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- KRGPXXHMOXVMMM-UHFFFAOYSA-N nicotianamine Natural products OC(=O)C(N)CCNC(C(O)=O)CCN1CCC1C(O)=O KRGPXXHMOXVMMM-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940097258 other antihypertensives in atc Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000007888 peripheral angioplasty Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229950008688 pivopril Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- BSHDUMDXSRLRBI-JOYOIKCWSA-N rentiapril Chemical compound SCCC(=O)N1[C@H](C(=O)O)CS[C@@H]1C1=CC=CC=C1O BSHDUMDXSRLRBI-JOYOIKCWSA-N 0.000 description 1
- 229950010098 rentiapril Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229950006241 saprisartan Drugs 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- OSDQJFVHDVAJSD-UHFFFAOYSA-M sodium;2-[2-butyl-3-[[4-[(2-carboxybenzoyl)amino]phenyl]methyl]-5-chloroimidazol-4-yl]propanoate Chemical compound [Na+].CCCCC1=NC(Cl)=C(C(C)C([O-])=O)N1CC(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C(O)=O OSDQJFVHDVAJSD-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229950005696 utibapril Drugs 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229950009999 zabicipril Drugs 0.000 description 1
- 229950004433 zolasartan Drugs 0.000 description 1
- FIKYECRHLXONOX-UHFFFAOYSA-N zolasartan Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(OC(=C2Br)C=3C(=CC=CC=3)C3=NNN=N3)C2=C1 FIKYECRHLXONOX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Electrotherapy Devices (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15143699P | 1999-08-30 | 1999-08-30 | |
| PCT/EP2000/008461 WO2001015674A2 (en) | 1999-08-30 | 2000-08-30 | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA77151C2 true UA77151C2 (en) | 2006-11-15 |
Family
ID=22538761
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002032518A UA77151C2 (en) | 1999-08-30 | 2000-08-30 | Use of ramipril for prevention of cardiovascular events |
| UAA200600263A UA88265C2 (ru) | 1999-08-30 | 2006-01-11 | Применение ингибитора ренин-ангиотензиновой системы для профилактики диабета |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200600263A UA88265C2 (ru) | 1999-08-30 | 2006-01-11 | Применение ингибитора ренин-ангиотензиновой системы для профилактики диабета |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US20040087645A1 (sr) |
| EP (1) | EP1216038B1 (sr) |
| JP (1) | JP4870888B2 (sr) |
| KR (2) | KR20020040795A (sr) |
| CN (1) | CN1268331C (sr) |
| AT (1) | ATE303800T1 (sr) |
| AU (3) | AU7649100A (sr) |
| BG (2) | BG110003A (sr) |
| BR (1) | BR0013704A (sr) |
| CA (1) | CA2382549C (sr) |
| CZ (1) | CZ300687B6 (sr) |
| DE (1) | DE60022525T2 (sr) |
| DK (1) | DK1216038T3 (sr) |
| EE (1) | EE05670B1 (sr) |
| ES (1) | ES2246894T3 (sr) |
| HK (1) | HK1048267B (sr) |
| HR (1) | HRP20020170A2 (sr) |
| HU (1) | HUP0203326A3 (sr) |
| IL (2) | IL148127A0 (sr) |
| ME (1) | ME00429B (sr) |
| MX (1) | MXPA02001694A (sr) |
| NO (1) | NO331616B1 (sr) |
| NZ (2) | NZ517468A (sr) |
| PL (1) | PL353199A1 (sr) |
| RS (1) | RS50377B (sr) |
| RU (2) | RU2276997C2 (sr) |
| SK (1) | SK2692002A3 (sr) |
| TR (1) | TR200200515T2 (sr) |
| UA (2) | UA77151C2 (sr) |
| WO (1) | WO2001015674A2 (sr) |
| ZA (1) | ZA200201470B (sr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1776954A3 (en) * | 1997-10-17 | 2009-11-11 | Ark Therapeutics Limited | The use of inhibitors of the renin-angiotensin system for the treatment of stroke |
| CN101011390A (zh) * | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| IL148127A0 (en) * | 1999-08-30 | 2002-09-12 | Aventis Pharma Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
| GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
| SG148838A1 (en) * | 2000-08-22 | 2009-01-29 | Boehringer Ingelheim Pharma | Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors |
| US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
| EP1314425A4 (en) * | 2000-08-30 | 2004-06-02 | Sankyo Co | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE |
| US20030158090A1 (en) * | 2001-07-23 | 2003-08-21 | Ulrik Pedersen-Bjergaard | Renin-angiotensin system in diabetes mellitus |
| GB0119460D0 (en) * | 2001-08-09 | 2001-10-03 | Ark Therapeutics Ltd | The use of inhibitors of the renin-angiotensin system |
| US6576256B2 (en) | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| WO2003032963A2 (en) * | 2001-10-17 | 2003-04-24 | Aventis Pharma Deutschland Gmbh | Method of reducing type 2 diabetes in high risk patients |
| JP2005511631A (ja) * | 2001-11-23 | 2005-04-28 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 脳血管障害発作の急性期における高血圧症の治療 |
| DE10229180A1 (de) * | 2002-06-28 | 2004-01-29 | Aventis Pharma Deutschland Gmbh | Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen |
| EP1382334A1 (en) * | 2002-07-11 | 2004-01-21 | Université de Picardie Jules Verne | Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
| US6936639B2 (en) * | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
| WO2004035051A1 (en) * | 2002-10-16 | 2004-04-29 | Recordati Ireland Limited | Lisinopril/lercanidipine combination therapy |
| JP2006515877A (ja) * | 2003-01-16 | 2006-06-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管、心肺、肺又は腎疾患の予防又は治療のための医薬併用剤 |
| DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| BRPI0406987A (pt) | 2003-01-31 | 2006-01-10 | Sankyo Co | Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral |
| DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
| US7169805B2 (en) * | 2003-05-28 | 2007-01-30 | Nicox S.A. | Captopril derivatives |
| EP1648515B1 (en) * | 2003-07-16 | 2012-11-21 | Boehringer Ingelheim International GmbH | Chlorthalidone combinations |
| WO2005011586A2 (en) | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2005030202A1 (en) * | 2003-09-26 | 2005-04-07 | Novartis Ag | Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders |
| NZ586285A (en) * | 2004-03-17 | 2011-12-22 | Novartis Ag | Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X) |
| JP2008503546A (ja) * | 2004-06-23 | 2008-02-07 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｎｅｐ阻害剤、内因性エンドセリン産生系阻害剤およびａｔ１受容体アンタゴニスト阻害剤を含有する医薬組成物 |
| JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
| JP2008519063A (ja) * | 2004-11-05 | 2008-06-05 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | 安定化ラミプリル組成物及びその製造方法 |
| WO2006079496A1 (en) * | 2005-01-26 | 2006-08-03 | Lek Pharmaceuticals D.D. | New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance |
| EP1898951B1 (en) * | 2005-06-27 | 2013-02-27 | Daiichi Sankyo Company, Limited | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| WO2007053406A1 (en) * | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinations of antihypertensive and cholesterol lowering agents |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| US20070185065A1 (en) * | 2006-02-03 | 2007-08-09 | Vikramjit Chhokar | Combination therapy for coronary artery disease |
| CA2661598A1 (en) * | 2006-08-28 | 2008-03-06 | Sanofi-Aventis Deutschland Gmbh | Methods of lowering glucose levels |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| CN101534798B (zh) * | 2006-10-30 | 2012-02-15 | 韩诺生物制约株式会社 | 包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物 |
| US8394845B2 (en) | 2006-10-30 | 2013-03-12 | Hanall Biopharma Co., Ltd. | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor |
| RU2453307C2 (ru) * | 2006-10-30 | 2012-06-20 | Ханол Биофарма Ко.Лтд | Комплексная фармацевтическая композиция с контролируемым высвобождением, содержащая блокаторы рецепторов ангиотензина-ii и ингибиторы гидроксиметилглутарил-кофермент а-редуктазы |
| GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
| GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
| RU2400223C1 (ru) * | 2009-03-30 | 2010-09-27 | Илья Николаевич Медведев | Способ нормализации функциональной реактивности сердечно-сосудистой системы при сочетании артериальной гипертонии со стенокардией i-ii функциональных классов |
| NZ596064A (en) * | 2009-04-30 | 2014-03-28 | Reddy’S Lab Ltd Dr | Fixed dose drug combination formulations |
| WO2011063339A1 (en) * | 2009-11-23 | 2011-05-26 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl donors for the treatment of pulmonary hypertension |
| CA2782110A1 (en) * | 2009-12-07 | 2011-06-16 | Johns Hopkins University | N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives |
| CN102753519B (zh) * | 2009-12-07 | 2015-08-05 | 约翰斯霍普金斯大学 | 二酰基化的羟基胺衍生物 |
| SI2538924T1 (sl) | 2010-02-24 | 2014-09-30 | Sanofi-Aventis Deutschland Gmbh | Trdne farmacevtske formulacije ramiprila in amlodipin bezilata in njihova priprava |
| BR112013015826A2 (pt) * | 2010-12-21 | 2016-07-12 | Silanes Sa De Cv Lab | composição estável de agentes redutores de colesterol, agentes anti-hipertensivos e agentes antiagregantes plaquetários |
| BR102012020648A2 (pt) * | 2012-08-17 | 2014-12-09 | Hypermarcas S A | Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido |
| KR101579656B1 (ko) * | 2013-12-12 | 2015-12-22 | 가천대학교 산학협력단 | 프라바스타틴과 발사르탄을 포함하는 약학 조성물 |
| CN110833620A (zh) * | 2018-08-15 | 2020-02-25 | 王镕 | 血管紧张素转化酶抑制剂在防治自身免疫性疾病及相应的并发症中的用途 |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5612114B2 (sr) * | 1974-06-07 | 1981-03-18 | ||
| US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| US4450171A (en) * | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
| DE3226768A1 (de) * | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
| US4448784A (en) * | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
| US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| US4722810A (en) * | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US5684016A (en) * | 1984-04-12 | 1997-11-04 | Hoechst Aktiengesellschaft | Method of treating cardiac insufficiency |
| DE3413710A1 (de) * | 1984-04-12 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur behandlung der herzinsuffizienz |
| CH672792A5 (sr) | 1985-02-19 | 1989-12-29 | Sandoz Ag | |
| US5231080A (en) * | 1985-10-15 | 1993-07-27 | Hoechst Aktiengesellschaft | Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease |
| EP0241201A3 (en) | 1986-04-07 | 1990-05-23 | Merck & Co. Inc. | Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure |
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US4749688A (en) * | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| DE3633496A1 (de) * | 1986-10-02 | 1988-04-14 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln |
| FR2607004B1 (fr) * | 1986-11-20 | 1990-06-01 | Synthelabo | Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine |
| DE3704661A1 (de) * | 1987-02-14 | 1988-08-25 | Hoechst Ag | Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung |
| US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
| JPH0657707B2 (ja) | 1987-05-25 | 1994-08-03 | 吉富製薬株式会社 | ピペリジン化合物 |
| DE3739690A1 (de) * | 1987-11-24 | 1989-06-08 | Hoechst Ag | Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen |
| EP0331014A3 (de) * | 1988-03-02 | 1991-10-23 | THERA - Patent Verwaltungs-GmbH | Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe |
| US5217958A (en) * | 1988-03-03 | 1993-06-08 | E. R. Squibb & Sons, Inc. | 1,2-hydroxy phosphonates and derivatives thereof |
| US4804770A (en) * | 1988-04-29 | 1989-02-14 | E. R. Squibb & Sons, Inc. | Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors |
| DE3818245A1 (de) * | 1988-05-28 | 1989-12-07 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln |
| SG139553A1 (en) | 1988-10-13 | 2008-02-29 | Novartis Ag | 7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof |
| WO1990005531A1 (en) * | 1988-11-21 | 1990-05-31 | Abbott Laboratories | Method for treating vascular diseases |
| CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| DE3926606A1 (de) * | 1989-08-11 | 1991-02-14 | Hoechst Ag | Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie |
| US5061694A (en) * | 1989-10-23 | 1991-10-29 | E. R. Squibb & Sons, Inc. | Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor |
| US5212165A (en) * | 1989-10-23 | 1993-05-18 | E. R. Squibb & Sons, Inc. | Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor |
| CA2026686A1 (en) | 1989-10-30 | 1991-05-01 | Werner Tschollar | Method for preventing onset of type ii diabetes employing an ace inhibitor |
| US5223516A (en) * | 1990-03-22 | 1993-06-29 | E. R. Squibb & Sons, Inc. | 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
| US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
| US5166143A (en) * | 1990-05-31 | 1992-11-24 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing an ace inhibitor |
| US5140012A (en) * | 1990-05-31 | 1992-08-18 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing pravastatin |
| US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| CA2042526A1 (en) | 1990-06-11 | 1991-12-12 | Adeoye Y. Olukotun | Method for preventing a second heart attack employing an hmg coa reductase inhibitor |
| CA2048699A1 (en) | 1990-09-04 | 1992-03-05 | Abraham Sudilovsky | Method for preventing or treating cerebro-vascular disease employing ceronapril |
| US5470975A (en) * | 1990-10-16 | 1995-11-28 | E.R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
| CA2053340C (en) | 1990-10-18 | 2002-04-02 | Timothy P. Burkholder | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| US5430145A (en) * | 1990-10-18 | 1995-07-04 | Merrell Dow Pharmaceuticals Inc. | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| CA2052014A1 (en) | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
| US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| GB9027199D0 (en) | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| US5157025A (en) | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| US5506361A (en) * | 1991-05-08 | 1996-04-09 | Theupjohn Company | Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same |
| JPH05112533A (ja) | 1991-05-08 | 1993-05-07 | Upjohn Co:The | イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤 |
| GB9110635D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
| US5225401A (en) * | 1991-08-12 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Treatment of congestive heart failure |
| US5202322A (en) * | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
| US5256667A (en) * | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| ZA927211B (en) | 1991-09-27 | 1993-03-24 | Merrell Dow Pharma | Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE. |
| AU657793B2 (en) | 1991-09-27 | 1995-03-23 | Merrell Pharmaceuticals Inc. | Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
| JPH06107661A (ja) | 1991-10-24 | 1994-04-19 | Upjohn Co:The | イミダゾール誘導体およびこれを有効成分とする医薬組成物 |
| US5350752A (en) | 1991-12-16 | 1994-09-27 | E. R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
| DK9200258U4 (da) | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Farmaceutisk præparat indeholdende enalapril til brug mod hypertension |
| US5219856A (en) * | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
| US5972990A (en) * | 1992-04-10 | 1999-10-26 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| US5977160A (en) * | 1992-04-10 | 1999-11-02 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| US5552397A (en) * | 1992-05-18 | 1996-09-03 | E. R. Squibb & Sons, Inc. | Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase |
| HU223663B1 (hu) * | 1992-05-15 | 2004-11-29 | Merrel Dow Pharmaceuticals Inc. | Enkefalináz és ACE gátló hatású 9-[(2-acetil-tio-3-fenil)-propanoil-amino]-piridazo[1,2-a][1,2]diazepin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények |
| US5554625A (en) * | 1992-07-17 | 1996-09-10 | Merck & Co., Inc. | Substituted biphenylmethylimidazopyridines |
| US5266583A (en) * | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
| WO1994007492A1 (en) | 1992-10-06 | 1994-04-14 | The Upjohn Company | Use of 4-hydrazono-1,4-dihydro-pyridine and/or 4-hydrazino-pyridine derivatives for treatment of hypertension and congestive heart failure |
| US5504080A (en) * | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
| GB9223860D0 (en) * | 1992-11-13 | 1993-01-06 | Glaxo Group Ltd | Chemical compounds |
| DE4308504A1 (de) | 1993-03-18 | 1994-09-22 | Knoll Ag | Neue Verwendung einer Kombination aus Verapamil und Trandolapril |
| DE4309553A1 (de) * | 1993-03-24 | 1994-09-29 | Bayer Ag | Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat |
| HUT71494A (en) | 1993-06-11 | 1995-11-28 | Eisai Co Ltd | Pharmaceutical compositions containing of condensed heterocyclic amino acid derivatives |
| US5508272A (en) * | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| US5362772A (en) * | 1993-07-09 | 1994-11-08 | E. I. Du Pont De Nemours And Company | Crosslinked microgel for cathodic electrocoating compositions |
| US5362727A (en) * | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
| WO1995013063A1 (en) | 1993-11-09 | 1995-05-18 | Merck & Co., Inc. | HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION |
| US5525723A (en) * | 1993-11-18 | 1996-06-11 | Bristol-Myers Squibb Co. | Compounds containing a fused multiple ring lactam |
| US6369103B1 (en) | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
| ES2079315B1 (es) * | 1994-02-24 | 1996-10-16 | Uriach & Cia Sa J | Nuevas imidazopiridinas. |
| IL112639A0 (en) | 1994-03-11 | 1995-05-26 | Bristol Myers Squibb Co | A pharmaceutical composition containing pravastin |
| AU696868B2 (en) | 1994-03-29 | 1998-09-17 | Merck & Co., Inc. | Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles |
| ES2105939B1 (es) * | 1994-08-02 | 1998-07-01 | Uriach & Cia Sa J | Nuevos pirazoles con actividad antagonista de la angiotensina ii. |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW483763B (en) | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| ES2205023T3 (es) | 1995-02-10 | 2004-05-01 | G.D. SEARLE & COMPANY | Combinacion de inhibidor de la enzima converitidora de angiotensina y antagonista de aldosterona para el tratamiento de la hipertrofia ventricular. |
| EP0738510A3 (fr) | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
| US5656603A (en) * | 1995-05-31 | 1997-08-12 | Loyola University Of Chicago | Aminopeptidase P inhibitors and uses thereof |
| TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| ES2175098T3 (es) | 1995-06-07 | 2002-11-16 | Searle & Co | Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo. |
| GB2308064A (en) | 1995-10-31 | 1997-06-18 | Merck & Co Inc | Treatment of congestive heart failure with a growth hormone secretagogue |
| AU2252297A (en) | 1996-01-31 | 1997-08-22 | Technology Licensing Co., L.L.C. | Method of diagnosis and treatment and related compositions and apparatus |
| EP0795327A1 (en) | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| JP2000513356A (ja) | 1996-06-24 | 2000-10-10 | メルク エンド カンパニー インコーポレーテッド | エナラプリルとロサルタンの組成物 |
| JPH1081633A (ja) * | 1996-07-16 | 1998-03-31 | Sankyo Co Ltd | 医薬組成物 |
| IL130599A0 (en) | 1997-01-10 | 2000-06-01 | Merck & Co Inc | Use of angiotensin II antagonists to treat symptomatic heart failure |
| CA2300165A1 (en) | 1997-08-26 | 1999-03-04 | Merck & Co., Inc. | Cholesterol-lowering therapy |
| US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
| GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| EP1776954A3 (en) | 1997-10-17 | 2009-11-11 | Ark Therapeutics Limited | The use of inhibitors of the renin-angiotensin system for the treatment of stroke |
| IL137979A0 (en) | 1998-03-04 | 2001-10-31 | Takeda Chemical Industries Ltd | Production, release preparation for aii antagonist-sustained and use thereof |
| ES2552639T3 (es) | 1998-07-10 | 2015-12-01 | Novartis Pharma Ag | Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos |
| BR9914098A (pt) | 1998-09-30 | 2001-07-31 | Warner Lambert Co | Método para impedir ou retardar revascularização à base de cateter |
| US6403856B1 (en) * | 1998-10-19 | 2002-06-11 | Uop Llc | Process for separating alkylaromatic hydrocarbons |
| DE19913528A1 (de) | 1998-12-21 | 2000-06-29 | Sanol Arznei Schwarz Gmbh | Neue Verwendung von Moexipril |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| WO2000067737A2 (en) | 1999-05-07 | 2000-11-16 | The Brigham And Women's Hospital, Inc. | USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION |
| WO2000071751A1 (en) | 1999-05-21 | 2000-11-30 | Myriad Genetics, Inc. | Diabetes gene |
| EP1076091A1 (en) | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| IL148127A0 (en) | 1999-08-30 | 2002-09-12 | Aventis Pharma Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| CA2381926A1 (en) | 1999-08-31 | 2001-03-08 | Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| CA2406077C (en) | 2000-04-10 | 2010-07-20 | Nicholas J. Wald | Formulation for the prevention of cardiovascular disease |
| CN1440283A (zh) | 2000-04-12 | 2003-09-03 | 诺瓦提斯公司 | 有机化合物的联合形式 |
| WO2001078747A1 (de) | 2000-04-18 | 2001-10-25 | Bayer Aktiengesellschaft | Verwendung von cse-hemmern zur behandlung von herzinsuffizienz |
| GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
| US20030158090A1 (en) * | 2001-07-23 | 2003-08-21 | Ulrik Pedersen-Bjergaard | Renin-angiotensin system in diabetes mellitus |
| US20050065203A1 (en) * | 2001-10-17 | 2005-03-24 | Salim Yusuf | Method of reducing type 2 diabetes in high risk patients |
| JP2005511631A (ja) * | 2001-11-23 | 2005-04-28 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 脳血管障害発作の急性期における高血圧症の治療 |
-
2000
- 2000-08-30 IL IL14812700A patent/IL148127A0/xx unknown
- 2000-08-30 TR TR2002/00515T patent/TR200200515T2/xx unknown
- 2000-08-30 UA UA2002032518A patent/UA77151C2/uk unknown
- 2000-08-30 HU HU0203326A patent/HUP0203326A3/hu not_active Application Discontinuation
- 2000-08-30 DE DE60022525T patent/DE60022525T2/de not_active Expired - Lifetime
- 2000-08-30 ME MEP-2008-643A patent/ME00429B/me unknown
- 2000-08-30 CN CNB008113947A patent/CN1268331C/zh not_active Expired - Fee Related
- 2000-08-30 PL PL00353199A patent/PL353199A1/xx not_active Application Discontinuation
- 2000-08-30 NZ NZ517468A patent/NZ517468A/en not_active IP Right Cessation
- 2000-08-30 CZ CZ20020770A patent/CZ300687B6/cs not_active IP Right Cessation
- 2000-08-30 CA CA002382549A patent/CA2382549C/en not_active Expired - Fee Related
- 2000-08-30 JP JP2001519888A patent/JP4870888B2/ja not_active Expired - Fee Related
- 2000-08-30 RS YUP-85/02A patent/RS50377B/sr unknown
- 2000-08-30 AU AU76491/00A patent/AU7649100A/en not_active Abandoned
- 2000-08-30 WO PCT/EP2000/008461 patent/WO2001015674A2/en not_active Ceased
- 2000-08-30 DK DK00965906T patent/DK1216038T3/da active
- 2000-08-30 ES ES00965906T patent/ES2246894T3/es not_active Expired - Lifetime
- 2000-08-30 HR HR20020170A patent/HRP20020170A2/xx not_active Application Discontinuation
- 2000-08-30 EE EEP200200086A patent/EE05670B1/xx not_active IP Right Cessation
- 2000-08-30 KR KR1020027002626A patent/KR20020040795A/ko not_active Ceased
- 2000-08-30 KR KR1020127009682A patent/KR20120055730A/ko not_active Ceased
- 2000-08-30 EP EP00965906A patent/EP1216038B1/en not_active Revoked
- 2000-08-30 MX MXPA02001694A patent/MXPA02001694A/es active IP Right Grant
- 2000-08-30 HK HK03100570.5A patent/HK1048267B/zh not_active IP Right Cessation
- 2000-08-30 RU RU2002107985/15A patent/RU2276997C2/ru not_active IP Right Cessation
- 2000-08-30 BR BR0013704-9A patent/BR0013704A/pt not_active Application Discontinuation
- 2000-08-30 SK SK269-2002A patent/SK2692002A3/sk unknown
- 2000-08-30 AT AT00965906T patent/ATE303800T1/de active
-
2002
- 2002-01-28 BG BG110003A patent/BG110003A/bg unknown
- 2002-01-28 BG BG106360A patent/BG65474B1/bg unknown
- 2002-02-12 IL IL148127A patent/IL148127A/en unknown
- 2002-02-21 ZA ZA200201470A patent/ZA200201470B/en unknown
- 2002-02-27 NO NO20020978A patent/NO331616B1/no not_active IP Right Cessation
-
2003
- 2003-10-28 US US10/694,001 patent/US20040087645A1/en not_active Abandoned
-
2004
- 2004-01-20 NZ NZ530702A patent/NZ530702A/en not_active IP Right Cessation
- 2004-12-02 US US11/001,028 patent/US20050101658A1/en not_active Abandoned
-
2005
- 2005-09-13 AU AU2005209687A patent/AU2005209687A1/en not_active Abandoned
- 2005-12-30 RU RU2005141759/15A patent/RU2005141759A/ru not_active Application Discontinuation
-
2006
- 2006-01-11 UA UAA200600263A patent/UA88265C2/ru unknown
- 2006-07-21 US US11/490,061 patent/US7368469B2/en not_active Expired - Lifetime
-
2008
- 2008-05-22 US US12/125,313 patent/US20080287403A1/en not_active Abandoned
-
2009
- 2009-02-25 AU AU2009200746A patent/AU2009200746B8/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA77151C2 (en) | Use of ramipril for prevention of cardiovascular events | |
| CA2859704C (en) | Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent | |
| MXPA04003022A (es) | Metodo para reducir diabetes tipo 2 en pacientes de alto riesgo. | |
| ZA200409200B (en) | Combination of angiotensin II receptor blocker and betablocker for secondary prevention of myocardial infarction | |
| US20050065203A1 (en) | Method of reducing type 2 diabetes in high risk patients | |
| WO2007051007A2 (en) | Combination of antihypertensives with cholesterol-lowering agent | |
| KALAITZIDIS et al. | Antihypertensive Drug–Induced Iatrogenic Cardiovascular Syndromes | |
| EP1611886A2 (en) | Inhibitors of the renin-angiotensin system for the prevention of cardiovascular disorders | |
| CA2488370A1 (en) | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events | |
| NZ627251B2 (en) | Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent |